Advanced Search

 

Study ID Status Title Patient Level Data
H3B106026 Completed A PET study using [11C] GSK189254 to establish the dose, plasma concentration and brain receptor occupancy relationship of GSK239512, a histamine H3 antagonist, in healthy subjects
H3B109689 Completed A single blind, placebo-controlled, randomised study in mild to moderate Alzheimer’s disease patients to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK239512, a selective histamine H3 receptor antagonist Study Listed on ClinicalStudyDataRequest.com
HGS1006-C1056 Completed A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 76-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects with Systemic Lupus Erythematosus (SLE) Study Listed on ClinicalStudyDataRequest.com
HGS1006-C1057 Completed A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Study Listed on ClinicalStudyDataRequest.com
HGS1021-C1063 Completed A randomized, single-blind, placebo-controlled study to evaluate the safety and tolerability of raxibacumab (human monoclonal antibody to B. anthracis protective antigen) in healthy subjects Study Listed on ClinicalStudyDataRequest.com
HGS1021-C1069 Completed An Open-Label Study to Evaluate the Immunogenicity and Safety of Raxibacumab (Human Monoclonal Antibody to B. anthracis Protective Antigen) Administered in Healthy Subjects Study Listed on ClinicalStudyDataRequest.com
HH3104994 Completed A randomised, double blind, placebo controlled, two way crossover, three phase study to investigate the trial models; Vienna Challenge Chamber, in and out of season and Park study in season and the clinical efficacy of repeat doses of fluticasone propionate in subjects with seasonal allergic rhinitis (SAR).
HH3110161 Completed A double-blind, placebo-controlled, randomized cross-over single dose escalation study and a double-blind, placebo-controlled, randomised parallel group 7-days once daily repeat dose study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of oral H1/H3 dual antagonist compound in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
HHI110157 Completed A double-blind, placebo-controlled, randomized single dose escalation study and a double-blind, placebo-controlled, randomised parallel group 14-days once daily repeat dose study to investigate safety, tolerability and pharmacokinetics of an intranasal H1/H3 dual antagonist compound in healthy male subjects Study Listed on ClinicalStudyDataRequest.com
HMA110015 Completed A Two-Part Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Oral Doses of GSK256073A, in a Randomized, Single-Blind, Dose Escalation study in Healthy Adult Subjects
HMA110541 Completed A Second Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single and a Repeat Oral Dose of GSK256073A in Healthy Adult Subjects
HMA111316 Completed A Study to Evaluate the Ability of the HM74A agonist GSK256073A to Block Niacin-induced Flushing in Healthy Adult Subjects
HPR10006 Completed A pilot, phase II, open-label, single arm study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of GW640385 when administered with ritonavir in combination with NRTIs for 48 weeks in HIV-1 infected adults
HPR20001 Terminated Phase IIB, Randomized, Multicenter, Parallel Group, Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effect of Four Blinded Dosing Regimens of GW640385X/ritonavir Compared to Open-label Current PI therapy in HIV-1 infected, Protease Inhibitor Experienced Adults for 2 weeks with Long-term Assessment (>48 weeks) of Safety, Pharmacokinetic and Antiviral Activity of Selected 385/RTV Dosing Regimen(s) vs. a Ritonavir-boosted, Protease Inhibitor Containing Regimen
HPV-Meta-analysis-201110 Completed Integrated Safety Summary of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®)
HS2100275 Completed An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients Study Listed on ClinicalStudyDataRequest.com
HS2101951 Completed Clinical Evaluation of Valaciclovir Hydrochloride: 256U87 in Patients with Chickenpox - Open Uncontrolled Study.
HS210914 Completed An open-label, single-dose, multicenter, pharmacokinetic, safety and tolerability study of valaciclovir oral suspension in infants and children. Study Listed on ClinicalStudyDataRequest.com
HSP108233 Terminated A Double-Blind, Parallel, Randomized, Placebo-Controlled, Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK625433 in Healthy Subjects and in Subjects who are Chronically Infected with Hepatitis C.
HSV Meta analyses Completed Meta analyses on pregnancy outcomes with respect to the effect of Herpes Simplex Virus (HSV) antigen and of the adjuvant (AS04)
HTP103265 Completed An open label, non-randomized positron emission tomography study in healthy male subjects to investigate brain 5-HT1A receptor occupancy, pharmacokinetics and safety of single oral doses of GSK163090, using the ligand [11C]-WAY100635.
HTP110333 Completed A randomized, single-blind, placebo-controlled, 2 part study to evaluate the safety and tolerability of GSK163090 at single and repeat doses in subjects with MDD
HYT104152 Completed A Phase I Study to Characterize the Pharmacokinetics of Topotecan at 4 mg/m2 Administered Weekly as a 30-Minute Intravenous Infusion in Patients with Cancer
HYT105962 Completed A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer
HYT109091 Completed A Phase I Open-label Study of the Safety, Tolerability, and Pharmacokinetics of Two Schedules of Oral Topotecan in combination with Pazopanib in Subjects with Advanced Solid Tumors

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.